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Edited by Sandro SonninoAbstract The tumour suppressor phosphatase and tensin
homologue deleted on chromosome 10 (PTEN) shares homology
with protein tyrosine phosphatases (PTPases). Similarly, bis-
peroxovanadium (bpV) molecules that are well-established
PTPase inhibitors were shown to inhibit PTEN, but at up to
100-fold lower concentrations. The preference and potency of the
bpVs towards PTEN was validated in vivo as demonstrated by:
(i) an increase of Ser473 phosphorylation of protein kinase B
(PKB) at similar low nanomolar doses, (ii) the lack of any eﬀect
on the PKB phosphorylation in the PTEN negative cell line
UM-UC-3, (iii) the ability to rescue Ly294002-induced
phosphoinositide 3-kinase inhibition and (iv) a lack of tyrosine
phosphorylation at low nanomolar doses.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Phosphatase and tensin homologue deleted on chromosome
10 (PTEN) is a recently identiﬁed tumour suppressor that is
either mutated or deleted in many cancer cells [1–4]. This
protein shows dual phosphatase activity, dephosphorylating
both protein [1] and lipid substrates [5], but it displays a higher
speciﬁcity towards 3-phosphorylated phosphoinositides (PI)
such as PtdIns(3)P, PtdIns(3,4)P2 and PtdIns(3,4,5)P3 [6].
3-Phosphorylated lipids are generated by the phosphoinositide
3-kinases (PI 3-kinases) in response to an extracellular stimu-
lation by growth factors. In dephosphorylating intracellular* Corresponding author. Fax: +44-20-7594-5207.
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Abbreviations: bpV, bisperoxovanadate; bpV(HOpic), dipotassium
bisperoxo(5-hydroxypyridine-2-carboxyl)oxovanadate; bpV(bipy),
potassium bisperoxo(bipyridine)oxovanadate; bpV(phen), potassium
bisperoxo(1,10-phenanthroline)oxovanadate; bpV(pic), dipotassium
bisperoxo(pyridine-2-carboxyl)oxovanadate; DTT, dithiothreitol;
GST, glutathione S-transferase; IPTG, isopropyl-b-D-thiogalactopyr-
anoside; NCS, newborn calf serum; PI 3-kinase, phosphoinositide
3-kinase; PtdIns(3,4,5)P3dC16, L-a-D-myo-phosphatidylinositol 3,4,5-
triphosphate 3-O-phospho-linked, D(+)-sn-1,2-di-O-hexadecanoylgly-
ceryl; PKB, protein kinase B; pNPP, para-nitrophenylphosphate;
PTEN, phosphatase and tensin homologue deleted on chromosome 10;
PTPase, protein tyrosine phosphatase
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doi:10.1016/j.febslet.2004.03.102PtdIns(3,4,5)P3, PTEN counteracts the action of PI 3-kinases
[7] thereby terminating certain downstream signalling path-
ways [8]. The major downstream target of PTEN seems to be
the protein kinase B (PKB), also referred to as Akt [9,10],
which is phosphorylated at two major sites (Thr308 and
Ser473) in a PI 3-kinase-dependent fashion [11].
Vanadate is a well-characterised competitive reversible in-
hibitor for protein tyrosine phosphatases (PTPases) [12–15]. In
particular, vanadate derivatives such the bisperoxovanadium
(bpV) have been employed as PTPase inhibitors [16,17] and
insulin mimetics [18–21]. Since PTEN shares with the PTPases
the same active centre, the CX5R motif [22], we hypothesised
that bpV compounds should also inhibit PTEN. In this study,
we conﬁrmed this hypothesis by characterising the bpVs with
respect to their inhibitory potency and speciﬁcity, in vitro and
in vivo. Our results show that these novel PTEN inhibitors are
eﬀective new tools, which will be very useful to further cha-
racterise signalling pathways downstream of PTEN.2. Materials and methods
2.1. Chemical synthesis
Vanadium oxide (V2O5) and pyridine-2-carboxylic acid (picolinic
acid) were purchased from Sigma–Aldrich and used as received. The
synthesis of dipotassium bisperoxo(pyridine-2-carboxyl)oxovanadate
(bpV(pic)) was performed as previously described [23], and the purity
and quality tested by elemental analysis (performed by the University
of North London) as well as 51V NMR and IR spectroscopy.
2.2. Cloning and expression of PTEN
The coding region of the DNA sequence of human PTEN was cloned
into a pGEX-4T2 expression vector (Pharmacia). Protein expression was
induced overnight in the Escherichia coli DH5a strain using 100 lM
isopropyl-b-D-thiogalactopyranoside (IPTG) at 18 C. Glutathione
S-transferase (GST)-fusion protein was puriﬁed according to the manu-
facturer’s manual using glutathione–Sepharose 4B (Pharmacia). Protein
integritywas conﬁrmedonaWestern blot usingGSTantibody (Novagen).
2.3. Determination of IC50 values for PTEN and tyrosine phosphatases
Enzyme activity of recombinant PTEN was measured in 200 mM
Tris, pH 7.4, containing 50 ng/ll BSA, 150 lM synthetic dipalmitoyl-
PtdIns(3,4,5)P3 (Cell Signals) and 0.25% (w/v) octyl glycoside (Sigma)
at 30 C for 30 min. In order to stop the enzyme reaction, 0.7 vol of
colour reagent (2.3 mg/ml malachite green in 3.6 M HCl and 17 mM
ammonium molybdate) was added to the assay. The mixture was al-
lowed to develop for 20 min and the absorbance at 625 nm was
measured [24,25]. PTPase assays were performed using the synthetic
substrate para-nitrophenylphosphate (pNPP) and the phosphatases
PTP-1B and PTP-b (Upstate Biotechnology) in 25 mM HEPES, pH
7.2, containing 50 mM NaCl, 5 mM dithiothreitol (DTT), 2.5 mM
EDTA, 100 lg/ml BSA and 1 mM pNPP (Sigma) for 15 min at 30 C.
The linear increase of absorbance was monitored every 30 s at a
wavelength of 410 nm. All experiments were repeated in triplicate.
Calculations for IC50 values were performed using GraphPad Prism.blished by Elsevier B.V. All rights reserved.
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NIH3T3 cells (passage 5–20) were grown in 10% newborn calf serum
(NCS) DMEM (Invitrogen) in 6-well plates at 37 C and 5% CO2.
Starvation of the cells was carried out over 72 h in DMEM containing
0.5% NCS. Prior stimulation of the cells medium was changed to 0%
DMEM. UM-UC-3 (passage 5–20), which is a PTEN bladder tumour
cell line [26,27] was grown in 10% MEM (Invitrogen), starved with
0.5% MEM also for three days and ﬁnally incubated with serum free
MEM.
2.5. Western Blot analysis
Cell lysates (NIH 3T3 and UM-UC3) were loaded on 10% SDS–
PAGE and transferred to PVDF membranes for PKB analysis and
nitrocellulose for phosphotyrosine detection. The membranes were
then blocked (5% milk powder in TBST) and subsequently analysed
for PKB phosphorylation using an anti-phospho-PKB (Ser473) anti-
body (NEB) or tyrosine phosphorylation employing an anti phos-
photyrosine antibody (4G10) according to the manufacturer’s
instructions. To control for equal loading, the amount of tubulin and
PKB was analysed in parallel.
2.6. Phosphorylation of tyrosine residues in NIH3T3 cells
NIH3T3 cells were grown and starved as described earlier. After 72
h starvation, cells were incubated for 15 min with 10% NCS, 0.5 lg/ml
insulin, 10, 1, 0.1 and 0.01 lM bpV(pic) and potassium bisperoxo(1,10-
phenanthroline)oxovanadate (bpV(phen)), respectively. In addition,
cells were co-treated with the lowest dose of bpV and 0.5 lg/ml insulin.
Cell lysates were analysed on Western Blots using an anti phospho-
tyrosine antibody (Upstate).
2.7. Cytotoxicity assay
Cytotoxicity of bpV compounds was measured with MTT assays.
NIH3T3 cells were resuspended in serum-free media and exposed to
concentrations of all four bpV compounds between 1 mM and 0.1 nM
for 2 h. MTT solution (ﬁnal concentration of 5 mg/ml) (Lancaster
Synthesis Ltd.) was added to the cells which were further incubated for
4 h. Cell pellets were resuspended in DMSO containing 0.1 M HCl and
measured at 570 nm.3. Results and discussion
3.1. PTEN is inhibited by bpV compounds, in vitro
PTEN has been described as a tumour suppressor, which is
mutated in many cancer tissues [1,4,28,29] and exerts this role
mainly by the negative regulation of the PI 3-kinase/PKB
signalling pathway [7,9,10]. Many researchers who are cur-
rently characterising the role of PTEN in signalling and disease
rely on the employment of PTEN null cell lines, such as glio-
blastoma [30] or UM-UC cells [31], PTEN knockout of cells
[10], which are not accessible in fully diﬀerentiated systems
such as muscle cells or neurons. Such eﬀorts could be sub-
stantially boosted if speciﬁc inhibitors were available, which in
conjunction with knockout models could be used to distin-
guish between scaﬀolding eﬀects and catalytic function of the
deleted PTEN as well as opening up new biological systems.
Given that PTPases and PTEN share considerable
homology in their active site, we reasoned that the previouslyTable 1
IC50 values for bpV compounds for the phosphoinositide 3-phosphatase PT
Enzyme N,N ligand
bpV(bipy) bpV(phen)
PTEN 18 nM 0.8 38 nM 2.4
PTP-b 60.3 nM 9.6 343 nM 88.5
PTP-1B 164 nM 22.6 920 nM 45.2
Phosphatase assays were performed as described in Section 2. The IC50 valucharacterised PTPase inhibitors [16,17], bpV compounds,
could be targeting the phosphatidylinositol 3-phosphatase
PTEN as well [6]. Testing several diﬀerent compounds in vitro
(Table 1) revealed that bpVs with polar N,O ligands [dipo-
tassium bisperoxo(5-hydroxypyridine-2-carboxyl)oxovanadate
(bpV(HOpic)) and bpV(pic)] had a strong preference towards
PTEN (IC50: 20–40 nM), while bpVs with the neutral N,N li-
gands [potassium bisperoxo(bipyridine)oxovanadate (bpV(bi-
py)) and bpV(phen)] seemed to be more promiscuous targeting
both PTPases (PTP-1B and PTP-b) and PTEN, although with
distinct aﬃnities. With respect to PTEN, it can be concluded
that all bpVs inhibit PTEN with 10- to 100-fold lower con-
centrations than PTPases. While PTEN binds all four mole-
cules in a similar fashion, PTPases seem to distinguish in terms
of size and charge, which is probably due to the diﬀerential
spatial arrangement in the catalytic site of the two targets,
since the active site of PTEN [32] is much wider than the
corresponding tyrosine phosphatase structure [33].
Although bpVs have been investigated towards their ability
to target tyrosine phosphatases in the past, to our knowledge
the four bpVs employed here have not been comprehensively
analysed in their eﬀectiveness on the two PTPases, PTP-1B and
PTP-b. Recently, IC50 values for bpVs were obtained for the
alkaline phosphatase [34] and for insulin receptor dephos-
phorylation [16], the latter being linked to tyrosine phospha-
tase inhibition, revealing no signiﬁcant diﬀerences between the
N,N and N,O compounds. Thus, the observed preference of
the tyrosine phosphatases, PTP-1B and PTP-b, for the N,N
ligand containing bpVs might be a characteristic for the par-
ticular enzymes employed here.
3.2. bpVs stimulated PKB phosphorylation at nanomolar
concentrations
Guided by the above-described in vitro characteristics, we
investigated whether the four bpVs could inhibit PTEN in
vivo. Any loss of PTEN activity will increase PtdIns(3,4,5)P3
levels if PI 3-kinases are suﬃciently active. Therefore, one
would expect a dose-dependent activation of PKB, a well
characterised downstream target of PTEN-dependent signal-
ling [35], after treatment with bpVs. Thus, we used PKB
phosphorylation as a monitor for the cellular PtdIns(3,4,5)P3
level in NIH3T3 cells. Since starved ﬁbroblasts need a certain
dose of growth factors in order to show drug dependent
changes in PKB phosphorylation (R.D. Byrne and R. Wo-
scholski, unpublished observation), all samples were stimu-
lated with 0.5 lg/ml insulin.
As shown in Fig. 1(a), the tested compounds induced the
phosphorylation of PKB in a dose-dependent manner. No
activation could be established with concentrations up to 10
nM, however, at higher concentrations a signiﬁcant enhance-
ment of the phosphorylated PKB signal was observed. ThreeEN and the protein tyrosine phosphatases PTP-b and PTP-1B
N,O ligand
bpV(HOpic) bpV(pic)
14 nM 2.3 31 nM 1.7
4.9 lM 0.9 12.7 lM 3.2
25.3 lM 2.9 61 lM 10.5
es are shown as the meansS.E. of triplicate experiments.
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Fig. 2. Counteraction of Ly294002-induced inhibition of PKB phos-
phorylation by bpV(pic). Quiescent NIH3T3 cells were pre-treated
with indicated concentrations of Ly294002 and incubated with or
without 200 nM bpV(pic) for 5 min, followed by a stimulation with 10
lg/ml insulin for 15 min. Phosphorylation of PKB in the cell samples
was analysed by Western blotting and optical densitometry (NIH
Image). The values were presented as the meansS.E. taken from
three independent experiments.
Fig. 1. Dose-dependent inhibition of PTEN by bpV compounds, in
vivo. Starved NIH3T3 (a) and UM-UC-3 (b) cells were incubated with
the indicated concentrations of bpVs for 5 min and stimulated for 15
min with 0.5 lg/ml insulin. For comparison, full stimulation of the cells
was carried out by adding 10% NCS. Cell lysates were analysed by
Western blotting for PKB phosphorylation and equal loading (tubulin
and mass-PKB) as described in Section 2.
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(NIH Image) and the calculated IC50 value for bpV(pic) was
48 nM (8.5). This indicates that PTEN can also be inhibited
with low nanomolar concentrations of bpV compounds, in
vivo. To further validate whether bpVs target PTEN similar
experiments were performed employing the PTEN negative
tumour cell line UM-UC-3. As shown in Fig. 1(b), no signif-
icant PKB phosphorylation could be observed. Taking all
these observations together, we suggest that the activation of
the pathways downstream of PI 3-kinase is due to PTEN in-
hibition. Exposure of the bpVs in media overnight did not alter
their potency towards PTEN inhibition (data not shown), in-dicating that these molecules are highly stable in the applied
assay conditions.
3.3. PTEN inhibitor bpV(pic) can partly abrogate Ly294002
induced PKB inhibition
Ly294002 is a commonly used PI 3-kinase inhibitor which
reduces PKB phosphorylation [36]. Since PTEN is the natural
inhibitor of PI 3-kinases, we examined whether the bpV(pic) is
able to rescue Ly294002-induced PKB inhibition. Indeed, a
shift in the IC50 of Ly294002 could be clearly detected (Fig. 2),
providing further proof that bpVs act as PTEN inhibitors.
3.4. The bpV inhibitors increased phosphorylation of tyrosine
residues in vivo
As pointed out above bpVs are well-characterised PTPase
inhibitors in the micromolar concentration range. In order to
conﬁrm the in vivo potency of the bpVs on PTPases, the ty-
rosine phosphorylation of total cell lysates was examined.
Western blot analysis (Fig. 3) for phosphorylated tyrosine
residues revealed the typical pattern of protein bands of
stimulated cells [37]. Although untreated cells showed a similar
pattern of detectable bands, these had much weaker intensity.
The highest degree of tyrosine phosphorylation could be de-
tected in cells treated with 10 lM bpV(pic), which is in
agreement with earlier investigation revealing that phosphor-
ylation of tyrosine residues was induced by 10 lM sodium
orthovanadate [37] or 0.5 mM pervanadate [38], and is more
potent than 10% NCS [39]. In contrast, 10 lM bpV(phen)
induced a weaker stimulation supporting the results presented
above (Table 1). Interestingly, low nanomolar concentrations
of the compounds that were eﬀective for PTEN inhibition did
not induce any signiﬁcant changes when compared to un-
stimulated cells, with or without co-treatment with 0.5 lg/ml
insulin. In conclusion, bpV compounds will target PTPases in
vivo only at micromolar concentrations, further corroborating
that these compounds are speciﬁc for inhibitors for PTEN in
the nanomolar concentration range.
3.5. Cytotoxicity of bpV compounds
The eﬀects of the bpVs on cell viability were carried out by
employing MTT assays, a means of measuring the activity of
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Fig. 4. Cytotoxicity of bpV compounds: NIH3T3 cells were treated
with concentrations of up to 1 mM bpV(pic), bpV(HOpic), bpV(bipy)
and bpV(phen) and MTT assays were undertaken as described in
Section 2. The results were presented as the means S.E. of triplicate
determinations.
Fig. 3. Phosphorylation of tyrosine residues induced by growth factors,
bpV(pic) and bpV(phen). Indicated concentrations of bpV(pic)
and bpV(phen) were applied to starved ﬁbroblasts for 15 min (see
Section 2). Molecular weight markers are indicated in kDa. The ﬁgure
shows a representative blot out of three.
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Fig. 4, all bpVs showed similar cytoxicity signiﬁcantly killing
cells at concentrations equal or higher than 100 lM. This in-
dicated that nanomolar doses, which can inhibit PTEN phos-
phatase activity in vitro and in vivo, do not aﬀect cell viability.
In summary, newly discovered PTEN inhibitors, bpVs, were
characterised with respect to their properties and their role in
insulin mimetic signalling. We clearly show that bpVs prefer-
entially inhibit PTEN at nanomolar concentrations using four
independent approaches: (i) IC50 assays for PTEN and PTP-
ases in vitro, (ii) phospho-PKB Western blot analyses in
NIH3T3 and PTEN negative UM-UC-3 cells, (iii) counterac-
tion of Ly294002-induced PI 3-kinase inhibition and (iv)
phospho-tyrosine Western blot analyses in NIH3T3 cells.
Since the bpVs inhibit PTEN at concentrations where no sig-
niﬁcant cytotoxicity could be observed, these compounds will
be useful research tools for investigators analysing PI 3-kinase-
mediated signalling.Acknowledgements: A.C. Schmid was supported by the Medical
Research Council (UK).References
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